This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Other Forms of Systemic Sclerosis기타 형태의 전신경화증

Contents and key points
ItemDetails
A. Classification codesICD-10: M34.8 (Other forms of systemic sclerosis) | Special Copayment Reduction: V138 (rare disease)
B. SynonymsSystemic sclerosis with lung involvement (J99.1*) | Systemic sclerosis with myopathy (G73.7*)
C. Adult onsetLikelihood of first onset in adulthood very high — systemic sclerosis with lung involvement and systemic sclerosis with myopathy, which fall under other forms of systemic sclerosis (M34.8), are typically first diagnosed in adults in their 30s–60s. Pediatric onset is rare, and most cases first present in adulthood with Raynaud phenomenon, skin changes, muscle weakness, dyspnea, and so on.
1. HistoryHistory of recognition of lung and muscle involvement in systemic sclerosis → separate descriptions of SSc-ILD and SSc-myopathy in the 1960s–70s → NSIP pattern established as the main form of SSc-ILD in 2001 → nintedanib approved for SSc-ILD in 2019.
2. CausesCommon pathogenesis of systemic sclerosis (autoimmunity, vascular injury, fibrosis) + lung- or muscle-specific mechanisms. Anti-Scl-70 antibody (ILD); anti-PM-Scl, anti-Ku, and anti-U1-RNP antibodies (myositis overlap). Shared environmental and genetic factors.
3. GeneticsHLA-DRB1*11:04 (SSc-ILD); anti-PM-Scl and HLA-DR3/DQ2 (myositis overlap). Shared IRF5, STAT4, CD247. Specific autoantibody-HLA associations in SSc-polymyositis overlap. Polygenic complex inheritance.
4. General epidemiologyILD in about 40–60% of SSc patients, myositis overlap in 10–15%. ILD rate about 60% in the Korean KOSC. Female predominance. ILD frequency highest in anti-Scl-70–positive dcSSc.
5. PathophysiologyLung involvement: alveolar endothelial and epithelial injury → fibroblast activation → TGF-β excess → pulmonary interstitial fibrosis. Myopathy: endothelial injury of muscle microvessels → muscle inflammation (CD8+ T-cell infiltration) → muscle fiber necrosis.
6. SymptomsILD: progressive exertional dyspnea, dry cough, fatigue. Myopathy: proximal muscle weakness (difficulty climbing stairs and raising arms), myalgia, proximal muscle atrophy. Accompanied by skin and vascular symptoms of systemic sclerosis.
7. SignsILD: basal Velcro crackles, restrictive pattern on PFT (reduced FVC and DLCO), NSIP pattern on HRCT. Myopathy: proximal muscle weakness, elevated muscle enzymes (CK, LDH), myopathic findings on EMG, necrosis and inflammation on muscle biopsy.
8. ScreeningILD: PFT (FVC, DLCO) and chest HRCT at diagnosis, then PFT every 6–12 months. Myopathy: muscle enzymes (CK, LDH, aldolase), anti-PM-Scl and anti-Ku antibodies, EMG, muscle biopsy. Assessment of active myositis by MRI.
9. DiagnosisMeeting the 2013 ACR/EULAR criteria for systemic sclerosis + confirmation of ILD (HRCT or PFT abnormalities) or myopathy (elevated muscle enzymes + EMG + muscle biopsy). ICD-10 dual coding: M34.8+J99.1* or M34.8+G73.7*.
10. TreatmentILD: mycophenolate (MMF) + nintedanib combination. For severe progression, cyclophosphamide, ASCT. Myopathy: steroids + MTX or azathioprine. Severe: rituximab, IVIG. Combined with baseline treatment of systemic sclerosis.
11. PrognosisWith ILD, FVC < 70% predicts 5-year mortality. Progressive ILD (FVC decline >10% within 12 months) requires early aggressive treatment. With myopathy overlap, treatment response is generally good. Prognosis improves with multidisciplinary management.
12. PreventionPrimary: reducing silica and organic solvent exposure, smoking cessation. Secondary: early ILD screening in anti-Scl-70–positive individuals. Tertiary: monitoring ILD progression with regular PFT and HRCT, regular measurement of muscle enzymes, maintaining function with physical therapy and pulmonary rehabilitation.
13. ReferencesDistler O, et al. Nintedanib for SSc-ILD (SENSCIS). NEJM. 2019 … and 9 other papers

1. History

Other forms of systemic sclerosis (M34.8) is a code in the ICD-10 classification system that encompasses subtypes of systemic sclerosis not classified as progressive systemic sclerosis (M34.0) or CREST syndrome (M34.1); in particular, systemic sclerosis with lung involvement (interstitial lung disease, ILD) (dual-coded with J99.1*) and systemic sclerosis with myopathy (dual-coded with G73.7*) are the representative clinical entities. The history of these subtypes is understood together with the history of systemic sclerosis as a whole, through the development of clinical recognition of each organ involvement.

Lung involvement in systemic sclerosis has been reported since the late 19th century, but systematic research began in earnest after the mid-20th century with the clinical introduction of pulmonary function tests and chest X-rays. From the 1960s, it was confirmed that a restrictive pulmonary function pattern and reduced diffusing capacity (DLCO) are commonly found in patients with systemic sclerosis. In the 1970s–80s, the concept of alveolitis was proposed as a precursor stage of systemic sclerosis ILD, and neutrophil- or eosinophil-predominant cell fractions on bronchoalveolar lavage (BAL) were studied as prognostic factors. In the 1990s, high-resolution chest CT (HRCT) was introduced clinically and the imaging patterns of systemic sclerosis ILD were systematized, and the 2001 American Thoracic Society/European Respiratory Society (ATS/ERS) consensus established the nonspecific interstitial pneumonia (NSIP) pattern as the most common histopathologic-imaging pattern of SSc-ILD. In 2006, the SLS I (Scleroderma Lung Study I) trial demonstrated for the first time in a randomized controlled study that cyclophosphamide significantly suppressed FVC decline in SSc-ILD. In 2019, nintedanib was approved by the FDA as the first antifibrotic treatment for SSc-ILD on the basis of the SENSCIS trial results.

The overlap of systemic sclerosis and myositis was recognized through individual case reports in the 1960s–70s. When Bohan and Peter proposed classification criteria for polymyositis/dermatomyositis in 1976, the concept of systemic sclerosis–myositis overlap syndrome began to be established. In the 1980s–90s, anti-PM-Scl, anti-Ku, and anti-U1-RNP antibodies, among others, were discovered as autoantibodies associated with systemic sclerosis–myositis overlap, clarifying the immunological characteristics of this subtype. In particular, anti-PM-Scl antibody shows a strong association with overlap of systemic sclerosis and polymyositis/dermatomyositis, and study results have accumulated showing a relatively favorable prognosis in patients positive for this antibody. In Korea as well, cases of systemic sclerosis–myopathy overlap have been analyzed and reported, centered on the Korean College of Rheumatology and the Korean Society of Neuromuscular Disorders, and these patients are included in registration and management under the Special Copayment Reduction (V138) system.

Special subtypes included among the other forms are exposure-related (occupational and environmental) scleroderma-like syndromes, drug-induced scleroderma, and localized systemic sclerosis–like diseases, and research on their epidemiology, pathophysiology, and prognosis is ongoing. Use of the ICD-10 code M34.8 plays an important role in clinical practice in accurately recording major visceral involvement of systemic sclerosis and reflecting it in insurance claims.


2. Causes

Other forms of systemic sclerosis (M34.8) share the common pathogenesis of progressive systemic sclerosis (M34.0) and CREST syndrome (M34.1), namely the triad of autoimmunity–vascular injury–fibrosis, with organ-specific pathogenic mechanisms added according to each subtype.

Specific causal mechanisms of lung involvement (SSc-ILD): In systemic sclerosis, interstitial lung disease (ILD) is defined as fibrosis of the pulmonary interstitium, that is, the alveolar walls, interlobular connective tissue, and connective tissue around the bronchioles. Anti-Scl-70 (anti-topoisomerase I) antibody positivity is most strongly associated with SSc-ILD, and there is experimental evidence that this antibody plays a direct pathogenic role beyond being a mere marker of pulmonary fibrosis. Injury and activation of alveolar endothelial and epithelial cells (especially type II pneumocytes) are the initial events, after which chemokines (MCP-1/CCL2, IP-10/CXCL10) that recruit T cells, monocytes, and fibroblasts to the pulmonary interstitium are oversecreted. TGF-β1 differentiates lung fibroblasts into myofibroblasts and induces excess collagen production, completing pulmonary interstitial fibrosis. IL-6, IL-13, and CTGF also participate in the fibrotic circuit. Smoking is an independent risk factor that worsens SSc-ILD, because smoking directly amplifies alveolar inflammation and lung fibroblast activation.

Specific causal mechanisms of myopathy overlap: In cases where systemic sclerosis and myopathy overlap (SSc-myopathy overlap), injury to muscle microvascular endothelial cells and infiltration of CD8+ cytotoxic T cells and CD4+ T helper cells around muscle fibers are the core pathology. Associated autoantibodies include anti-PM-Scl (binding to the PM-100 and PM-75 antigens), anti-Ku, anti-U1-RNP, and anti-synthetase (anti-Jo-1, etc.), each showing different overlap syndrome patterns and clinical presentations. In anti-PM-Scl–positive patients, myositis is combined with relatively mild skin sclerosis, ILD, and Raynaud phenomenon. Abnormal expression of MHC I molecules on muscle fibers and cytotoxic T cell–mediated muscle fiber destruction cause muscle weakness and elevated muscle enzymes.

Common environmental and genetic factors: Occupational exposure to silica and organic solvents is associated not only with dcSSc but also with the development of SSc-ILD. A history of smoking worsens the severity of SSc-ILD. Infectious triggers (CMV, EBV) and molecular mimicry mechanisms may also trigger pulmonary or muscular autoimmune responses in some patients.


3. Genetics

The genetic background of other forms of systemic sclerosis (M34.8) consists of a combination of common systemic sclerosis susceptibility genes and subtype-specific genotypes. Systemic sclerosis with lung involvement and systemic sclerosis with myopathy each show characteristic HLA associations and autoantibody-genotype association patterns.

Genetic susceptibility to SSc-ILD: HLA-DRB1*11:04 is the risk HLA allele most strongly associated with anti-Scl-70 antibody–positive dcSSc and SSc-ILD. In GWAS studies, variants in non-HLA genes IRF5, STAT4, CD247, BLK, and TNPO3 (the transportin 3 gene) have been reported to be associated with SSc-ILD. In particular, it has been hypothesized that TNPO3 variants may cause abnormal immune cell transport related to pulmonary fibrosis. Variants in telomere length–related genes (TERT, TERC) are strongly associated with idiopathic pulmonary fibrosis (IPF), and the role of these variants in SSc-ILD is also being studied. Telomere shortening can accelerate fibrosis by promoting senescence of lung epithelial cells and an abnormal regenerative response.

Genetic susceptibility to SSc-myopathy overlap: Anti-PM-Scl antibody shows a strong association with HLA-DR3 (DRB1*03:01) and HLA-DQ2 (DQB1*02:01). This HLA combination is also a risk allele for myositis and systemic sclerosis, each as a standalone disease, suggesting that the two diseases share a genetically based tendency in immune response. When systemic sclerosis–myopathy overlap appears in anti-U1-RNP antibody–positive mixed connective tissue disease (MCTD), associations with HLA-DRB1*04:01 and DRB1*01:01 have been reported. In overlap of systemic sclerosis with antisynthetase syndrome positive for synthetase antibodies such as anti-Jo-1, HLA-DQA1*05:01 is known as a risk allele.

Shared non-HLA genes: IRF5, STAT4, CD247, BLK, and BANK1 are non-HLA susceptibility genes shared across systemic sclerosis subtypes and are also involved in SSc-ILD and SSc-myopathy overlap. Epigenetic changes, especially changes in DNA methylation of fibrosis- and inflammation-regulating genes such as FLI1 and HDAC4 in lung fibroblasts and muscle cells, are also observed in M34.8 subtypes. Because these epigenetic changes are reversible, they may become potential targets for epigenome editing–based treatment strategies.

Clinical use of autoantibodies: Autoantibody profiles are used in place of genotype testing for predicting clinical prognosis and making treatment decisions. In anti-Scl-70–positive patients, ILD screening and early initiation of immunosuppressive treatment are recommended. In anti-PM-Scl– or anti-Ku–positive patients, muscle enzymes and muscle function are assessed periodically, considering the possibility of myopathy overlap. In this way, the three-way association system of autoantibody–clinical subtype–genotype provides a practical basis for establishing individualized management strategies for M34.8 patients.


4. General epidemiology

The epidemiology of other forms of systemic sclerosis (M34.8) is understood by dividing it into systemic sclerosis with lung involvement and systemic sclerosis with myopathy. Because M34.8 is a diagnostic code reflecting specific organ involvement patterns of systemic sclerosis rather than a separate independent disease, its epidemiology is described based on the prevalence of each organ involvement in overall systemic sclerosis cohorts.

Epidemiology of SSc-ILD: The prevalence of HRCT-confirmed ILD in patients with systemic sclerosis is about 40–60%, reaching about 60–80% in anti-Scl-70–positive dcSSc. Clinically significant progressive ILD (FVC < 70% predicted or FVC decline of 10% or more within 12 months) occurs in about 15–25% of all SSc patients. The female predominance (about 75–80%) and age of onset in the 30s–50s are similar to systemic sclerosis overall. In Asian patients, particularly Korean and Japanese patients, the anti-Scl-70 positivity rate is higher than in Western patients, and the incidence of SSc-ILD also tends to be relatively higher. In Korean KOSC data, the rate of SSc-ILD is reported at about 60%. SSc-ILD, together with pulmonary arterial hypertension, is the most important cause of systemic sclerosis–related death, accounting for about 30–35% of systemic sclerosis–related deaths.

Epidemiology of SSc-myopathy overlap: The prevalence of clinical myopathy (proximal muscle weakness + elevated muscle enzymes or EMG/muscle biopsy abnormalities) in patients with systemic sclerosis is reported at about 10–15%. The anti-PM-Scl antibody positivity rate is about 3–8% in patients with systemic sclerosis and is relatively higher especially in patients of European descent. In Asian patients, the anti-PM-Scl antibody positivity rate is lower, and instead overlap syndromes associated with anti-Ku and anti-U1-RNP antibodies tend to be reported more often. Systemic sclerosis–polymyositis/dermatomyositis overlap (SSc-PM/DM overlap) is observed in about 5–10% of patients with systemic sclerosis. In this overlap syndrome, ILD is also frequently present, sometimes in the form of dual organ involvement.

Epidemiology of special subtypes: Systemic sclerosis–like syndromes related to occupational silica exposure occur in miners, quarry workers, construction workers, and others, and about 5–10% of patients with systemic sclerosis have a history of occupational silica exposure. Bleomycin-induced pulmonary fibrosis (similar to ILD) is a chemotherapy-related complication that must be differentiated from systemic sclerosis. Graft-versus-host disease (GVHD)–related sclerodermatous skin changes also resemble the clinical findings of systemic sclerosis and are considered in the differential diagnosis within the M34.8 category.


5. Pathophysiology

The pathogenesis of other forms of systemic sclerosis (M34.8) is understood as a complex process in which lung- or muscle-specific mechanisms are added to the common mechanisms of systemic sclerosis.

Pathogenesis of SSc-ILD: Pulmonary interstitial fibrosis begins with injury to alveolar endothelial cells (pulmonary capillaries) and type II alveolar epithelial cells (ATII). Chemokines (MCP-1, IP-10) secreted from injured pulmonary endothelial cells recruit monocytes, T cells, and mast cells to the pulmonary interstitium. Th2-skewed CD4+ T cells and M2-skewed macrophages (alternatively activated macrophages) secrete IL-4, IL-13, and TGF-β, activating lung fibroblasts. The TGF-β1/SMAD2/3 signaling pathway is the core fibrotic pathway, differentiating lung fibroblasts into myofibroblasts and inducing excess production of ECM (especially type I and III collagen). The Wnt/β-catenin pathway, PDGF receptor signaling, and the YAP/TAZ mechanosensing pathway also contribute to maintaining pulmonary fibrosis. Injury and abnormal regeneration of type II alveolar cells are known to induce epithelial-mesenchymal transition (EMT), replenishing the fibroblast population in the interstitium. Pulmonary vascular injury also coexists, and PAH may develop as pulmonary vascular involvement progresses.

Pathogenesis of SSc-myopathy: Injury to muscle microvascular endothelial cells is the initial event, and ischemia and reperfusion injury due to endothelial injury induce infiltration of inflammatory cells around muscle fibers. CD8+ cytotoxic T cells bind to muscle fibers abnormally expressing MHC I molecules and destroy them through the perforin-granzyme mechanism. Abnormal expression of MHC I molecules on muscle fibers is induced by endothelial injury, TLR activation, and interferon signaling. Autoantibodies (anti-PM-Scl, anti-Ku) secreted by CD4+ T cells and plasma cells cause additional damage to muscle fibers and vascular endothelium through complement-dependent cytotoxicity or antibody-dependent cellular cytotoxicity (ADCC). Intramuscular fibrosis also progresses as a result of chronic myositis, forming the final pathology of proximal muscle weakness and muscle atrophy. Because vascular lesions of systemic sclerosis can cause muscle ischemia so that muscle atrophy progresses independently of myositis (muscle fiber atrophy without inflammation in SSc-myopathy), distinguishing these two mechanisms is clinically important.


6. Symptoms

The symptoms of other forms of systemic sclerosis (M34.8) present as the common skin and vascular symptoms of systemic sclerosis with specific symptoms of lung or muscle involvement added.

Symptoms of lung involvement (SSc-ILD): The earliest symptom of ILD is exertional dyspnea, which at first appears only with moderate exercise such as climbing stairs or brisk walking and gradually occurs even with light daily activities. Dry cough is commonly present and is characterized by persistent repetition without sputum. Fatigue and general exercise intolerance also appear. With progression, dyspnea at rest, oxygen desaturation, and cyanosis appear. When pulmonary hypertension develops, dyspnea becomes more severe and chest pain, syncope, and lower-limb edema are added. Early ILD is often asymptomatic (asymptomatic ILD), so screening with pulmonary function tests and HRCT is important.

Symptoms of myopathy: The characteristic symptom of systemic sclerosis–related myopathy is proximal muscle weakness. Difficulty arises with movements that mainly use proximal muscles, such as climbing stairs, rising from a chair, raising the arms, and reaching for objects overhead. Myalgia may be present but tends to be less prominent than in polymyositis/dermatomyositis. In a chronic course, proximal muscle atrophy and weight loss may occur. In some patients, asymptomatic myopathy with only elevated muscle enzymes and no muscle weakness is found. Muscle ischemia due to vascular lesions of systemic sclerosis (ischemic myopathy) can also cause proximal muscle weakness, so differentiation from inflammatory myopathy is needed.

Systemic and skin/vascular symptoms: Patients with M34.8 also experience Raynaud phenomenon, skin sclerosis, and esophageal dysmotility, the common symptoms of systemic sclerosis. The overall symptom burden of an individual patient is determined by the frequency and severity of Raynaud phenomenon, the extent of skin sclerosis (dcSSc or lcSSc), and the presence or absence of esophageal symptoms. When ILD and myopathy are present together (dual organ involvement), the symptom burden is greater and functional impairment is more severe.


7. Signs

The physical signs of other forms of systemic sclerosis (M34.8) consist of the common findings of systemic sclerosis plus specific signs of lung or muscle involvement.

Physical and laboratory signs of SSc-ILD: Fine inspiratory crackles of the "Velcro" type are heard on inspiration at the lung bases (especially both lower lobes). This is the sound produced when the fibrotic pulmonary interstitium is forced open on inspiration. With progression, tachypnea, use of accessory respiratory muscles, and oxygen desaturation at rest (SpO2 < 95%) appear. Clubbing of fingers is rarer than in IPF but may occur. On pulmonary function tests, a restrictive pattern with reduced FVC and TLC (total lung capacity) and reduced DLCO are the functional indicators of ILD. On chest HRCT, the nonspecific interstitial pneumonia (NSIP) pattern: ground-glass opacity and reticulation predominant at the bases of both lower lobes, with sublobular and subpleural distribution; honeycombing is rare. A usual interstitial pneumonia (UIP) pattern is also observed in about 10–15%.

Physical and laboratory signs of SSc-myopathy: On physical examination, proximal muscle weakness (upper limbs: deltoid, biceps; lower limbs: quadriceps, iliopsoas) is observed, and reduced grip strength and difficulty raising the heels may also occur. Proximal muscle atrophy becomes prominent over a long course. Because skin sclerosis of systemic sclerosis covers the skin over the muscles, palpation of the muscle surface may be difficult. Elevated serum muscle enzymes (CK, LDH, aldolase, AST) are indicators of active myositis. Positivity for anti-PM-Scl, anti-Ku, or anti-U1-RNP antibodies suggests myopathy overlap. On electromyography (EMG), a myopathic pattern (increased insertional activity, abnormal spontaneous activity, small, short polyphasic motor unit potentials) is observed. Muscle biopsy confirms infiltration of inflammatory cells (CD8+ T cells, macrophages), muscle fiber necrosis and regeneration, and abnormal MHC I expression. Muscle MRI allows assessment of myositis activity (fatty signal replacement, edema).

Common signs of systemic sclerosis: Common physical signs of systemic sclerosis are present, such as skin sclerosis (mRSS score), nailfold capillaroscopy abnormalities, telangiectasia, sclerodactyly, the triphasic color change of Raynaud phenomenon, and ischemic digital tip ulcers.


8. Screening

Screening in other forms of systemic sclerosis (M34.8) consists of two stages: ① assessment of whether ILD and myopathy are present at the diagnosis of systemic sclerosis, and ② surveillance for progression of complications in already confirmed patients.

SSc-ILD screening: Immediately after confirmation of systemic sclerosis, pulmonary function tests (FVC, FEV1, DLCO, TLC) are performed as a baseline in all patients. If baseline DLCO < 70%, FVC < 70% predicted, or FVC/DLCO ratio > 1.6 (suspected PAH or ILD), chest HRCT is performed immediately. Even without symptoms, early chest HRCT is recommended in anti-Scl-70–positive dcSSc patients. Thereafter, PFT follow-up is performed every 6–12 months, and HRCT is repeated if clinical symptoms worsen or PFT declines. The 6-minute walk test (6MWT) assesses exercise capacity and oxygen desaturation.

SSc-myopathy screening: In patients with systemic sclerosis who have proximal muscle weakness, myalgia, or excessive fatigue, muscle enzymes (CK, LDH, aldolase, AST, ALT) and anti-PM-Scl, anti-Ku, and anti-U1-RNP antibody tests are performed immediately. If elevated muscle enzymes are confirmed, EMG and muscle MRI are performed to assess for active myositis. If necessary, histological confirmation is obtained by MRI-guided muscle biopsy. Regular CK measurement in asymptomatic patients is not a recommendation, but annual testing is considered in anti-PM-Scl– or anti-Ku–positive patients.

Surveillance of dual organ involvement: In patients with both ILD and myopathy confirmed, both organs are followed simultaneously. PFT and muscle enzyme measurements are performed according to their respective follow-up schedules, and pulmonary toxicity is monitored during immunosuppressive treatment for myositis. Because steroid administration carries a risk of renal crisis in SSc, blood pressure and renal function are monitored more intensively.


9. Diagnosis

The diagnosis of other forms of systemic sclerosis (M34.8) consists of two steps: ① diagnosis of systemic sclerosis itself (2013 ACR/EULAR classification criteria) and ② confirmation of specific organ involvement (ILD or myopathy). In ICD-10, M34.8 is dual-coded as the primary diagnosis with J99.1* (lung involvement) or G73.7* (myopathy) as an additional code.

Diagnosis of systemic sclerosis: The 2013 ACR/EULAR classification criteria are applied (met with a total of 9 or more points). The M34.8 code is used for patients who meet the diagnostic criteria for systemic sclerosis without being classified as M34.0 (progressive systemic sclerosis) or M34.1 (CREST syndrome), and is used particularly in combination with specific organ involvement codes (J99.1*, G73.7*) to clearly describe the clinical entity.

Confirmation of SSc-ILD: ILD is diagnosed when chest HRCT shows an ILD pattern consistent with systemic sclerosis (mainly NSIP: ground-glass opacity and reticulation in both lower lobes, or rarely a UIP pattern). Even without HRCT, clinical ILD can be determined when PFT shows a restrictive pattern (FVC < 70% predicted, DLCO < 70% predicted) not explained by underlying disease (cardiac, PAH). Histological confirmation is rarely needed; video-assisted thoracoscopic lung biopsy (VATS biopsy) distinguishes NSIP, UIP, and other patterns. BAL is used supplementarily for differentiation from IPF (lymphocyte predominance on BAL supports NSIP).

Confirmation of SSc-myopathy: The 2017 EULAR/ACR classification criteria for idiopathic inflammatory myopathies are applied in the context of systemic sclerosis overlap. The combination of proximal muscle weakness + elevated muscle enzymes (CK) + myopathic EMG pattern + histological findings of myositis on muscle biopsy is the basis for diagnosis. Positivity for myositis-related autoantibodies such as anti-PM-Scl, anti-Ku, and anti-Jo-1 is supporting evidence. In systemic sclerosis, proximal muscle weakness can be caused not only by myositis but also by steroid myopathy, ischemic myopathy, or dystrophic myopathy, so differentiation is important.


10. Treatment

Treatment of other forms of systemic sclerosis (M34.8) follows a strategy of combining common treatment for systemic sclerosis with treatment specific to lung involvement or myopathy.

Treatment of SSc-ILD: Mycophenolate mofetil (MMF, target 2,000–3,000 mg/day) is recommended as first-line immunosuppressive treatment. In the SLS II study, MMF showed an effect on FVC maintenance equivalent to cyclophosphamide (CYC) with a more favorable toxicity profile. Nintedanib (2×150 mg/day) reduced the rate of FVC decline by about 44% compared with placebo in the SENSCIS trial (2019) and can be combined with MMF. In progressive ILD (FVC decline of 10% or more within 12 months or baseline FVC < 70%), MMF + nintedanib combination is now approaching the standard. Cyclophosphamide (CYC, oral or IV pulse) shows effects similar to MMF but is second-line because of toxicity (bladder toxicity, bone marrow suppression, risk of malignancy). Autologous hematopoietic stem cell transplantation (ASCT; SCOT and ASTIS trials) has advantages over MMF/CYC in long-term survival and ILD stabilization in severe progressive SSc-ILD and early dcSSc, but considering treatment-related mortality it is limited to selected young, healthy patients. Rituximab (anti-CD20) and tocilizumab (anti-IL-6R) are also used as adjunctive treatment in some SSc-ILD. High-dose corticosteroids (> 15 mg/day prednisone) are avoided as much as possible because of the risk of renal crisis, and when unavoidable, the principle is to use the minimum effective dose.

Treatment of SSc-myopathy: When active myositis is confirmed, steroids (prednisone 0.5–1 mg/kg/day) are used as initial treatment. However, because high-dose steroids carry a risk of renal crisis in systemic sclerosis, the goal is to taper as quickly as possible. As steroid-sparing immunosuppressants, methotrexate (MTX, 15–25 mg weekly) or azathioprine (AZA, 1–2 mg/kg/day) is used first-line. MTX is effective for both skin sclerosis and myositis and is particularly useful in early dcSSc. For treatment-resistant or relapsing myopathy, rituximab (RTX, 1,000 mg given twice 2 weeks apart, repeated every 6 months) is effective, with reductions in muscle enzymes and improved muscle strength reported. Intravenous immunoglobulin (IVIG, 2 g/kg over 5 days) is used as adjunctive treatment in acute severe myositis or steroid-intolerant patients. Calcineurin inhibitors (cyclosporine, tacrolimus) are also considered in myositis overlap.

Concurrent common treatment of systemic sclerosis: Common treatments for systemic sclerosis, such as for Raynaud phenomenon, PAH, GERD, and renal monitoring, are also given concurrently in M34.8 patients. In particular, gastrointestinal adverse effects (diarrhea, nausea) are common with nintedanib, so appropriate supportive care is needed. Physical therapy and pulmonary rehabilitation are effective in improving exercise tolerance in SSc-ILD patients.


11. Prognosis

The prognosis of other forms of systemic sclerosis (M34.8) varies greatly depending on the severity of major organ involvement (ILD, myopathy) and treatment response. SSc-ILD is a major cause of systemic sclerosis–related death, whereas SSc-myopathy tends to have a relatively good treatment response.

Prognosis of SSc-ILD: FVC < 70% predicted at diagnosis or extensive ILD (affected lung volume > 20% on HRCT) is a strong predictor of 5-year mortality. Limited ILD (FVC ≥ 70%, affected lung volume < 20%) has a relatively favorable course. A decline in FVC of 10% or more or in DLCO of 15% or more within 12 months defines progressive ILD and requires immediate intensification of treatment. Since the approval of nintedanib, its effect in slowing the rate of FVC decline in SSc-ILD has been demonstrated, but complete reversal of fibrosis is difficult to achieve with current treatment. Anti-Scl-70 positivity, low FVC early in the disease, and extensive HRCT changes are poor prognostic factors. ASCT has shown improved 5–10-year long-term survival in severe SSc-ILD, but there is treatment-related mortality (about 3–6%).

Prognosis of SSc-myopathy: Anti-PM-Scl–positive systemic sclerosis–myositis overlap syndrome generally shows a relatively favorable prognosis within the overall spectrum of systemic sclerosis. Treatment response to steroids and immunosuppressants is often better than in idiopathic polymyositis/dermatomyositis. When ILD is also present in SSc with myopathy, the prognosis may be worse. Sustained high-dose steroid use increases the long-term risk of steroid myopathy, osteoporosis, and infection, so steroid-sparing strategies are important. There are cohort studies reporting normalization of muscle enzymes and recovery of muscle strength in patients treated with rituximab, and when the treatment response is sustained, the prognosis may improve.

Integrated prognostic management: Patients with M34.8 require integrated management by a multidisciplinary team including rheumatology, pulmonology, neurology (myopathy), physical and occupational therapy, and dietitians. Comprehensive follow-up including regular PFT, muscle enzymes, muscle strength assessment, and quality-of-life measurement contributes to improved prognosis and early detection of complications.


12. Prevention

Prevention of other forms of systemic sclerosis (M34.8) consists of three stages: prevention of onset, early detection, and suppression of complication progression.

Primary prevention (reducing risk of onset): Reducing occupational silica exposure (protective equipment and environmental control for workers in mining, quarrying, and construction) and minimizing organic solvent exposure are the environmental prevention methods with the most evidence for reducing the risk of developing systemic sclerosis. Because smoking is an independent risk factor that worsens SSc-ILD, smoking cessation is essential. Education emphasizes the importance of smoking cessation especially in anti-Scl-70–positive patients at high risk of developing ILD. No specific primary prevention for myopathy is known, but regular appropriate exercise to maintain muscle health and caution with concomitant drugs that cause muscle damage (statins, etc.) are needed.

Secondary prevention (early detection): Immediately after confirmation of systemic sclerosis, baseline assessment of ILD (PFT, HRCT) and myopathy (muscle enzymes, autoantibodies) detects early organ involvement. In anti-Scl-70–positive dcSSc patients, early chest HRCT is recommended even without symptoms. When muscle weakness or myalgia is reported, muscle enzymes including CK and anti-PM-Scl and anti-Ku antibody tests are performed immediately to pursue early diagnosis of myopathy. Prompt initiation of immunosuppressive treatment after early detection is key to suppressing the progression of ILD and myopathy.

Tertiary prevention (suppressing complication progression): In patients with confirmed ILD, PFT follow-up every 6–12 months and immediate addition of nintedanib or treatment intensification when the progressive ILD criterion (FVC decline of 10% or more) is met are key to suppressing complication progression. During myopathy treatment, the steroid dose is minimized to lower the risk of steroid myopathy, osteoporosis, and renal crisis. Pulmonary rehabilitation (breathing exercises, strength training, aerobic exercise) improves exercise capacity and quality of life in SSc-ILD patients. Adequate nutritional intake (especially protein, vitamin D, calcium) and muscle-protective exercise minimize the progression of muscle atrophy in patients with myopathy. Vaccinations (influenza, pneumococcal, COVID-19) are essential for preventing infectious pneumonia in patients receiving immunosuppressive treatment.


13. References

  1. Distler O, Highland KB, Gahlemann M, et al. Nintedanib for systemic sclerosis–associated interstitial lung disease. N Engl J Med. 2019;380(26):2518-2528. DOI: 10.1056/NEJMoa1903076. PMID: 31112379.

  2. Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease (SLS I). N Engl J Med. 2006;354(25):2655-2666. DOI: 10.1056/NEJMoa055120. PMID: 16790698.

  3. Tashkin DP, Roth MD, Clements PJ, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II). Lancet Respir Med. 2016;4(9):708-719. DOI: 10.1016/S2213-2600(16)30152-7. PMID: 27469583.

  4. Sullivan KM, Goldmuntz EA, Keyes-Elstein L, et al. Myeloablative autologous stem-cell transplantation for severe scleroderma (SCOT). N Engl J Med. 2018;378(1):35-47. DOI: 10.1056/NEJMoa1703327. PMID: 29298160.

  5. Khanna D, Lin CJF, Furst DE, et al. Tocilizumab in systemic sclerosis (focuSSced). Lancet Respir Med. 2020;8(10):963-974. DOI: 10.1016/S2213-2600(20)30248-4. PMID: 32640245.

  6. Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017;390(10103):1685-1699. DOI: 10.1016/S0140-6736(17)30933-9. PMID: 28413064.

  7. Allenbach Y, Mammen AL, Benveniste O, et al. 224th ENMC International Workshop: Clinico-sero-pathological classification of immune-mediated necrotizing myopathies. Neuromuscul Disord. 2018;28(1):87-99. DOI: 10.1016/j.nmd.2017.09.016. PMID: 29183541.

  8. Packman Z, Oddis CV, Aggarwal R. Anti-PM-Scl antibody syndrome: a review. Curr Opin Rheumatol. 2020;32(6):577-582. DOI: 10.1097/BOR.0000000000000756. PMID: 32842020.

  9. Nihtyanova SI, Schreiber BE, Walker UA, et al. Prediction of pulmonary complications and long-term survival in systemic sclerosis. Arthritis Rheumatol. 2014;66(6):1625-1635. DOI: 10.1002/art.38390. PMID: 24578180.

  10. Kim GT, Kim J, Lee J, et al. Clinical features and organ damage in Korean patients with systemic sclerosis. J Korean Med Sci. 2021;36(10):e75. DOI: 10.3346/jkms.2021.36.e75. PMID: 33724741.